Externally Led-Patient Focused Drug Development (EL-PFDD) for Wilson Disease

We’re proud to announce that the U.S. Food and Drug Administration (FDA) will be attending our virtual Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting on Wilson disease on Thursday, January 29, 2026 from 10 a.m. to 3 p.m. ET.

This is a landmark opportunity for the Wilson disease community to speak directly to the FDA, product developers, clinicians, and academic researchers about what it truly means to live with Wilson disease—and what meaningful treatment looks like from the patient and caregiver perspective.